Menstrual cyclicity after metformin therapy in polycystic ovary syndrome

Obstetrics and Gynecology

Volumn 90, Issue 3, 1997, Pages 392-395

  Velázquez M , Elsy ^a   Acosta, Arnaldo ^a   Mendoza, Soaira G ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GLAFORNIL; GLUCOSE; INSULIN; LUTEINIZING HORMONE; METFORMIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; FERTILITY; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; MENSTRUAL CYCLE; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

ADULT; FEMALE; HUMANS; MENSTRUATION; METFORMIN; PERIODICITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES;

EID: 0030745921     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00296-2     Document Type: Article

References (28)

1. Frank S. Polycystic ovary syndrome. N Engl J Med. 333:1995;853-861.
2. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups, of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metabol. 65:1987;499-507.
3. Dunaif A, Futterweit W, Segal KR, Dobrjansky A. Profound peripheral resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes. 38:1989;1165-1174.
4. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 50:1988;197-212.
5. Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome. J Clin Invest. 83:1989;23-29.
6. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metabol. 67:1988;460-464.
7. Nestler JE, Powers LP, Matt DW. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metabol. 72:1991;83-89.
8. Matthei S, Greten H. Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane. Diabetes. 17:1991;150-158.
9. Perrielo G. Mechanisms of metformin action in NIDDM. Diabet Metabol Rev. 11:1995;43-50.
10. Barley CJ, Path MRC, Turner RC. Metformin. N Engl J Med. 29:1996;574-579.
11. De Fronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin dependent diabetic subjects. J Clin Endocrinol Metabol. 73:1991;1294-1301.
12. Vague P, Juhan-Vague Y, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglycerides levels in non-diabetic obese subjects. Thromb Haemost. 57:1987;326-328.
13. Velázquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:1994;647-654.
14. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 335:1996;617-623.
15. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metabol. 21:1961;1440-1447.
16. Yeh HC, Futterweit W, Thornton JC. Polycystic ovarian disease US features in 104 patients . Radiology. 163:1987;111-116.
17. Cook CL. Luteal-phase defect. Clin Obstet Gynecol. 34:1991;199-207.
18. Dunaif A, Scott D, Finegood D, Quintaba B, Whitcomb R. The insulin-sensitizing agent Troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metabol. 81:1996;3299-3306.
19. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system Localization, signaling mechanisms and functional aspects . Progr Neurobiol. 36:1991;343-362.
20. Adashi EY, Hsveh AJW, Yen SSC. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 108:1981;1441-1449.
21. Dunaif A, Scully RE, Andersen RN, Chapin DS, Crowley WF Jr. The effects of continuous androgen secretion of the hypothalamic-pituitary axis in women Evidence from a luteinized thecoma of the ovary . J Clin Endocrinol Metabol. 59:1984;389-393.
22. Givens JR, Andersen RN, Wiser WL, Donelson AJ, Coleman SA. A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease. J Clin Endocrinol Metabol. 41:1975;845-853.
23. Hillier S, Ross GT. Effects of exogenous testosterone on ovarian weight, follicular morphology and intraovarian progesterone concentration in estrogen-primed immature female rats. Biol Reprod. 20:1979;261-268.
24. Hsueh ADW, Billig H, Tsafiri A. Ovarian follicle atresia A hormonally controlled apoptotic process . Endocrinol Rev. 15:1994;707-724.
25. Uilenbroek JTJ, Wonlersen PJA, Van der Schoot P. Atresia in preovulatory follicles Gonadotropin binding in steroidogenic activity . Biol Reprod. 23:1980;219-229.
26. Louvet JP, Harman SM, Schreiber JR, Ross GT. Evidence for a role of androgens in follicular maturation. Endocrinology. 97:1975;366-372.
27. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells A review of structure/function relationships . Endocrinol Rev. 6:1985;371-399.
28. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxford). 36:1992;105-111.